Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.

Some prefer hair systems for better appearance and confidence, while others find them costly and inauthentic. Alternatives like minoxidil, finasteride, and hair transplants are also considered.

A user shared their experience with hair loss, initially using finasteride and minoxidil without satisfactory results, and later switching to hair systems, which they plan to use indefinitely. The user and others discussed the positive reactions, maintenance, and normalization of hair systems for men.

The user experienced significant hair regrowth using a combination of minoxidil, finasteride, various serums, and micro-needling, leading to increased confidence and consideration of a hair transplant. Despite initial baldness due to past health issues, the user is pleased with the progress and continues to use treatments like Pilgrim, Md Hair, Bodywise Roller, and Bouf serums.

P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.

A 27-year-old actor shared his positive experience with two hair transplant surgeries, highlighting the importance of customization and detail for a natural look. He is taking finasteride to prevent future hair loss.

Stem-cell hair transplants could potentially create thousands of grafts from a single donor graft, offering a solution for hair loss with DHT-resistant hair. Companies like Stemson Therapeutics and OrganTech are working on this technology, which may become available in the future, possibly reducing the cost and making it widely accessible.

The user shares their experience with a hair system, noting no one noticed the change except their girlfriend. They discuss the learning curve, maintenance tips, and their satisfaction with the results, feeling more confident and optimistic.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

The potential of using Verteporfin to prevent hair loss scars and possible regrowth, with two doctors currently testing it, although the price of a 15mg bottle is expensive.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

The conversation is about a person who underwent a hair transplant surgery after using Rogaine, finasteride, and Nutrafol. They received 2300 grafts and discussed the appearance and density of the transplant, with mixed opinions on the results and advice on future procedures.

A user trying to avoid an expensive hair transplant, and the replies suggesting they wait two years on treatment before deciding if they need a transplant or not.

Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermal papilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.

The conversation discusses hair loss and queries the effectiveness of treatments like PRP, Exosome therapy, peptides, and Stem Cell therapy. Specific treatments like Minoxidil, finasteride, and RU58841 are also mentioned.

Transplanting pubic and butt hair to the head is discussed humorously, highlighting pros like DHT resistance and cons like poor blending and appearance. Users joke about using treatments like Minoxidil, Finasteride, and RU58841 on unconventional donor areas.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

Balding is challenging, and relying on medications like finasteride is often seen as a better option than constantly shaving or trying to compensate in other areas. Many feel that societal expectations to "own it" or drastically change oneself to cope with baldness are unrealistic and burdensome.

Hair systems require frequent maintenance and can be costly, but a DIY approach with bi-weekly changes can help manage these issues. Minoxidil and finasteride were tried but not consistently used due to side effects and personal preferences.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

The conversation discusses the progress and potential of hair cloning by Stemson Therapeutics, questioning if it will be realized in the next 5-10 years or if it's just false hope. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.